Riskpilot← Back to searchSign inGet full accessAVP Holdings ApS
APSActiveCVR 37770191Geelsdalen 24Activities of holding companies · NACE 6421Est. 2016— employees
Revenue 2025
DKK -10K
+18% vs 2024
EBITDA margin
100.0%
-18% vs 2024
Equity ratio
95.7%
Financial strength
Net profit 2025
DKK 238K
+44% vs 2024
| Revenue | DKK -10K | +18% |
| EBITDA | DKK -10K | -18% |
| Net profit | DKK 238K | +44% |
| Total assets | DKK 953K | +7% |
| Equity | DKK 912K | +15% |
| Employees | — | — |
Legal name
AVP Holdings ApS
CVR number
37770191
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
31. maj 2016
Share capital
DKK 50.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene, eller af hele direktionen i forening.
Company purpose
Selskabets formål er at foretage investeringer i aktiviteter, som leverer rådgivning og serviceydelser til interesser, som driver forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler, medicinsk udstyr og/eller kosttilskud, og andre hermed relaterede aktiviteter.
Address
Geelsdalen 24
Phone
+4522663147
Email
avp@avp-biopharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -8 | -2 | -2 | -8 | -10 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -8 | -2 | -2 | -8 | -10 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -8 | -2 | -2 | -8 | -10 |
| Net financials | 281 | 217 | 257 | 176 | 242 |
| Profit before tax | 273 | 215 | 254 | 168 | 232 |
| Tax | 14 | 3 | 17 | 3 | -5 |
| Net profit | 259 | 212 | 237 | 165 | 238 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 706 | 641 | 778 | 893 | 953 |
| Equity | 505 | 608 | 740 | 795 | 912 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 200 | 33 | 38 | 98 | 41 |
| Total debt | 200 | 33 | 38 | 98 | 41 |
EBITDA margin
-983000.0%
This company
15.8%
Market median
-6221619% vs market
20212025
Equity ratio
95.7%
This company
38.2%
Market median
+151% vs market
20212025
Return on equity
26.0%
This company
18.4%
Market median
+41% vs market
20212025
Net profit margin
23753700.0%
This company
8.1%
Market median
+293255456% vs market
20212025
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AVP Holdings ApS 
AVP BioPharma Consult ApSBoard members of AVP Holdings ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|